|1.||Janjic, Nebojsa: 4 articles (05/2010 - 12/2005)|
|2.||Critchley, Ian A: 4 articles (12/2007 - 02/2002)|
|3.||Matsumoto, Tetsuro: 2 articles (06/2014 - 11/2002)|
|4.||Kawashima, Makoto: 2 articles (06/2012 - 02/2011)|
|5.||Hayashi, Nobukazu: 2 articles (06/2012 - 02/2011)|
|6.||Dubée, Vincent: 1 article (02/2015)|
|7.||Barros, David: 1 article (02/2015)|
|8.||Signorino-Gelo, François: 1 article (02/2015)|
|9.||McKinney, John D: 1 article (02/2015)|
|10.||Cuinet, Guillaume: 1 article (02/2015)|
07/01/1999 - "The results presented suggest that faropenem is a highly safe and effective antibiotic for the treatment of obstetric or gynecological infections of various kinds in an ambulatory setting."
02/01/2011 - "Cutaneous Mycobacterium chelonae infection successfully treated with faropenem."
02/01/2005 - "Faropenem, a new oral penem with broad spectrum activity, could be used as empirical treatment in infections due to unidentified anaerobes, but only a few investigations have been carried out on these bacteria. "
03/01/2003 - "Faropenem may be useful for treating infections caused by periodontal bacteria or oral flora."
09/01/1997 - "[Clinical evaluation of faropenem against infections in pediatric fields]."
06/01/2012 - "Multicenter randomized controlled trial on combination therapy with 0.1% adapalene gel and oral antibiotics for acne vulgaris: comparison of the efficacy of adapalene gel alone and in combination with oral faropenem."
02/01/2011 - "Efficacy of oral antibiotics on acne vulgaris and their effects on quality of life: a multicenter randomized controlled trial using minocycline, roxithromycin and faropenem."
02/01/2011 - "To clarify the difference between oral antibiotics, acne patients with moderate to severe inflammatory eruptions were randomized into three groups, and each patient was given minocycline (MINO), roxithromycin (RXM) or faropenem (FRPM) for 4 weeks, followed by 4 weeks of observation without any oral antibiotics. "
09/01/2003 - "Faropenem seems to be a promising antimicrobial agent for the treatment of adult and pediatric Streptococcus pneumoniae infections."
06/01/1999 - "In conclusion, levofloxacin and faropenem may be useful in the treatment of pneumococcal infections caused by organisms with decreased susceptibility to penicillin."
01/01/2008 - "Prospective, randomized, multicenter clinical trials have demonstrated noninferiority of faropenem to comparators for the treatment of acute bacterial sinusitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis, and uncomplicated skin and skin structure infections. "
01/01/2008 - "Replidyne is developing faropenem medoxomil, the ester-type prodrug of faropenem, for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP). "
07/01/2009 - "Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). "
|1.||Anti-Bacterial Agents (Antibiotics)
|7.||Anti-Infective Agents (Microbicides)
|9.||iclaprim (AR 100)